Table 2 Base-case cumulative virological response and HBV resistance probabilities for each rescue therapy
Rescue therapy | HBeAg (+) |  | BeAg (−) |  | Source |
|---|---|---|---|---|---|
| Â | Cumulative virological response (%) | Cumulative resistance (%) | Cumulative virological response (%) | Cumulative resistance (%) | Â |
ADV monotherapy | 1st year: 20.4 | 1st year: 1.6 | 1st year: 33.3 | 1st year: 0 | [9] |
| Â | 2nd year: 33.2 | 2nd year: 20.7 | 2nd year: 44.0 | 2nd year: 16.9 | [9] |
| Â | 3rd year: 38.8 | 3rd year: 39.5 | 3rd year: 47.5 | 3rd year: 31.4 | [9] |
| Â | 4th year: 41.2 | 4th year: 51.6 | 4th year: 51.0 | 4th year: 42.4 | [9] |
ADV and LAM combination therapy | 1st year: 47.0 | 1st year: 1.0 | 1st year: 60.0 | 1st year: 1.0 | |
| Â | 2nd year: 68.0 | 2nd year: 1.0 | 2nd year: 76.0 | 2nd year: 1.0 | |
| Â | Â | 3rd year: 1.0 | 3rd year: 97.0 | 3rd year: 1.0 | |
| Â | Â | 4th year: 8.0 | Â | 4th year: 8.0 | [29] |
ETV monotherapy§ | 1st year: 21.0 | 1st year: 1.0 | 1st year: 21.0 | 1st year: 1.0 | |
| Â | 2nd year: 39.5 | 2nd year: 10.9 | 2nd year: 39.5 | 2nd year: 10.9 | |
| Â | Â | 3rd year: 25.2 | Â | 3rd year: 25.2 | |
| Â | Â | 4th year: 36.4 | Â | 4th year: 36.4 | |
TDF monotherapy§ | 1st year: 45.8 | 1st year: 1.0 | 1st year: 45.8 | 1st year: 1.0 | [22] |
| Â | 2nd year: 64.4 | 2nd year: 2.0 | 2nd year: 64.4 | 2nd year: 2.0 | [22] |